What the research found

Guidelines recommend 150 minutes weekly of moderate cardiovascular activity for reducing cardiovascular disease risk—a threshold supported by major public health organizations and established in large cohort studies. However, the dose-response relationship is curved rather than linear: the largest health gains occur when moving from sedentary to minimally active, and meaningful benefit may appear below the 150-minute threshold. The 150-minute figure is pragmatic guidance rather than a biological threshold.

Recent large-scale analysis of nearly 147,000 participants (predominantly women in their 50s) identified a strength training sweet spot of 90–120 minutes weekly, associated with a 13% reduction in all-cause mortality, 19% reduction in cardiovascular mortality, and 27% reduction in neurological disease mortality. Earlier meta-analyses had suggested 60 minutes weekly as optimal, but as evidence has accumulated, the identified peak has shifted upward. Notably, benefits plateau above 120 minutes; more training doesn't confer additional mortality advantage.

Women appear to gain equal or greater health benefit from physical activity at lower total volumes than men do. Studies show women achieve similar survival benefits at roughly half the activity dose of men, and resistance training specifically has shown a stronger mortality signal in women than in men. A large cohort study found women reduced hypertension risk by approximately 14% through three to four weekly resistance sessions.

Why it matters for you

If you're tracking biomarkers like blood pressure, resting heart rate, or lipid profiles, this framework helps you understand which stimulus drives which adaptation. The 150-minute cardio prescription is well-established and familiar; the emphasis here shifts toward resistance work—specifically, hitting around 100 minutes weekly. For users logging training, this means if you're doing 20 minutes daily, you're hitting both targets without requiring marathon-length sessions.

The strength component matters most for the outcomes MyKine users typically monitor: all-cause mortality risk, blood pressure control, and physical function as you age. If you're female, the research suggests you may see meaningful risk reduction at lower total volumes than male peers—which means efficiency is on your side. For menopause-age users specifically, the evidence here comes largely from cohorts similar to you (average age 54, predominantly women), so these aren't extrapolations from younger populations.

The practical split—roughly 20 minutes moderate cardio plus 15 minutes strength daily—is designed to be sustainable rather than prescriptive. The source emphasizes this is a minimum, not a ceiling; if your current training exceeds this and you enjoy it, that's fine. The key takeaway for logging: if you're under 100 minutes of resistance work weekly, prioritizing that slice of your training may return larger mortality and disease-risk benefits than adding more cardio.

Caveats

  • The 90–120 minute strength-training finding is observational with self-reported activity; causation cannot be inferred, and no data exists on training intensity or adherence.
  • The strongest evidence for sex differences applies to total physical activity and mortality, not resistance training in isolation; resistance-specific sex-difference claims rest on fewer studies.
  • Cancer mortality in the large cohort showed different dose–response than other outcomes (lowest at very low volumes, not at 90–120 minutes), indicating benefits are not uniform across all causes.
  • The 150-minute cardio threshold is a pragmatic public health target, not a biological cliff; meaningful benefit may appear at lower doses.